Efficacy of Inhaled Treprostinil on Multiple Disease Progression Events in Patients with Pulmonary Hypertension due to Parenchymal Lung Disease in the INCREASE Trial

RATIONALE: The INCREASE study of inhaled treprostinil met its primary endpoint of change in 6-minute-walk distance at Week 16. In addition, there were significantly fewer clinical worsening events in patients receiving inhaled treprostinil. However, the incidence of multiple events in the same patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Nathan, Steven D., Tapson, Victor F., Elwing, Jean, Rischard, Franz, Mehta, Jinesh, Shapiro, Shelley, Shen, Eric, Deng, Chunqin, Smith, Peter, Waxman, Aaron
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Thoracic Society 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8787243/
https://www.ncbi.nlm.nih.gov/pubmed/34767495
http://dx.doi.org/10.1164/rccm.202107-1766OC

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8787243/
https://www.ncbi.nlm.nih.gov/pubmed/34767495
http://dx.doi.org/10.1164/rccm.202107-1766OC

Ejemplares similares